Nov 29, 2025

Featuring perspectives from Dr Komal Jhaveri and Dr Virginia Kaklamani, including the following topics: 

• Introduction: Oral Selective Estrogen Receptor Degraders (SERDs) for the General Medical Oncologist (0:00)
• SERD Monotherapy (13:34)
• SERD and CDK Inhibitor Combination — The EMBER-3 Study (35:58)
• SERDs for...

Nov 26, 2025

Featuring an interview with Dr Priyanka Sharma, including the following topics:

• T-DXd versus trastuzumab emtansine for high-risk HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of the DESTINY-Breast05 trial (0:00)
  • Geyer C...

Nov 21, 2025

Featuring perspectives from Dr Tanios Bekaii-Saab and Dr Kristen K Ciombor, including the following topics:

• Introduction: Assessment of HER2 Status (0:00)
• Case: An otherwise healthy woman in her early 50s with HER2-positive metastatic gallbladder cancer and multiple intrahepatic metastases — Jeremy Lorber, MD (7:33)

Nov 20, 2025

Featuring an interview with Dr Erika Hamilton, including the following topics:

• General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00)
• Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders...

Nov 19, 2025

Featuring a slide presentation and related discussion from Dr Erika Hamilton, including the following topics:

• Mechanisms of endocrine resistance; incidence of ESR1 mutations in breast cancer (0:00)
• Testing methods for ESR1 mutations in patients with breast cancer; therapeutic options for patients with ESR1-mutant...